

CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number  
**WO 2005/014585 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 405/04**,  
405/06, 405/14, 413/14, 417/14, A61K 31/395

(21) International Application Number:  
PCT/CA2004/001466

(22) International Filing Date: 6 August 2004 (06.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/493,336 8 August 2003 (08.08.2003) US

(71) Applicant (for all designated States except US):  
**ULYSSES PHARMACEUTICAL PRODUCTS INC.**  
[CA/CA]; 238 Ch. d'Orford-sur-le Lac, Eastman, Quebec  
J0E 1P0 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHAMBERLAND**,  
Suzanne [CA/CA]; 238 Ch. d'Orford-sr-le-Lac, Eastman,  
Quebec J0E 1P0 (CA). **MALOUIN, Francois** [CA/CA];  
238 Ch. d'Orford-sur-le-Lac, Eastman, Quebec J0E 1P0  
(CA).

(74) Agents: **SCHWARTZ, David, E.** et al.; Smart & Biggar,  
Suite 3300, 1000 de La Gauchetiere Street West, Montreal,  
Quebec H3B 4W5 (CA).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

Published:


— with international search report

(48) Date of publication of this corrected version:  
9 September 2005

(15) Information about Correction:  
see PCT Gazette No. 36/2005 of 9 September 2005, Sec-  
tion II

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS



(I)

proviso that at least one of R<sub>3</sub> and R<sub>4</sub> is halogen; and pharmaceutically acceptable salts thereof. The invention also includes pharma-  
ceutically acceptable formulations of said compounds which exhibit antibiotic activity against a wide spectrum of microorganisms  
including organisms which are resistant to multiple antibiotic families and are useful as antibacterial agents for treatment or prophy-  
laxis of bacterial infections, or their use as antiseptics, agents for sterilization or disinfection.

WO 2005/014585 A1

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number  
**WO 2005/014585 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 405/04**,  
405/06, 405/14, 413/14, 417/14, A61K 31/395

(21) International Application Number:  
PCT/CA2004/001466

(22) International Filing Date: 6 August 2004 (06.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/493,336 8 August 2003 (08.08.2003) US

(71) Applicant (for all designated States except US):  
**ULYSSES PHARMACEUTICALS PRODUCTS**  
INC. [CA/CA]; 238 Ch. d'Orford-sur-le Lac, Eastman,  
Quebec J0E 1P0 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHAMBERLAND**,  
Suzanne [CA/CA]; 238 Ch. d'Orford-sur-le-Lac, Eastman,  
Quebec J0E 1P0 (CA). **MALOUIN, Francois** [CA/CA];  
238 Ch. d'Orford-sur-le-Lac, Eastman, Quebec J0E 1P0  
(CA).

(74) Agents: **SCHWARTZ, David, E.** et al.; Smart & Biggar,  
Suite 3300, 1000 de La Gauchetiere Street West, Montreal,  
Quebec H3B 4W5 (CA).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS



(I)

(57) Abstract: The present invention includes novel  
compounds of the formula (I) wherein X is absent or  
trans or cis CHCH, R<sub>1</sub> is (C<sub>1</sub>-C<sub>10</sub>) alkyl unsubstituted  
or substituted by one to three hydroxy, (C<sub>1</sub>-C<sub>10</sub>) alkenyl  
unsubstituted or substituted by one to three hydroxy,  
(C<sub>1</sub>-C<sub>10</sub>) alkynyl unsubstituted or substituted by one to  
three hydroxy, or aryl unsubstituted or substituted by  
one to three hydroxy; R<sub>2</sub> is hydrogen, alkyl or aryl; R<sub>3</sub>  
and R<sub>4</sub> are, independently of each other, H, halogen, or

a solubilizing group, with the proviso that at least one of R<sub>3</sub> and R<sub>4</sub> is halogen; and pharmaceutically acceptable salts thereof. The  
invention also includes pharmaceutically acceptable formulations of said compounds which exhibit antibiotic activity against a wide  
spectrum of microorganisms including organisms which are resistant to multiple antibiotic families and are useful as antibacterial  
agents for treatment or prophylaxis of bacterial infections, or their use as antiseptics, agents for sterilization or disinfection.